License and Collaboration Agreements - Additional Information (Detail)	1 Months Ended	3 Months Ended
	Nov. 30, 2021 USD ($)	Mar. 31, 2023 USD ($) ProductCandidate	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
License Revenue [Line Items]
Milestone payment upon commencement of clinical trials in humans		$ 537,800,000
Milestone payment upon submission of regulatory approval filings		17,000,000.0
Milestone payment upon approval of commercial products by regulatory agencies		133,000,000.0
Milestone payment upon achievement of specified sales targets for licensed products		875,000,000.0
Deferred revenue, current and non-current		1,311,000	$ 3,333,000	$ 1,829,000	$ 3,333,000
Contract assets		2,000,000	1,126,000	0	$ 1,074,000
Aggregate transaction price of license agreements		$ 2,700,000
Aggregate transaction price of license agreements, expected satisfaction period		2 years
Revenue recognized upon achievement of development milestones		$ 2,000,000.0	0
Provision for credit losses		0	0
Accounts receivable, current		18,861,000		28,082,000
Accounts receivable, net		1,300,000		1,504,000
Other Current Assets [Member]
License Revenue [Line Items]
Net cost reimbursement due from collaborators		18,362,000		6,294,000
Due from Abeona		18,362,000		6,294,000
Abb Vie Collaboration And License Agreement
License Revenue [Line Items]
Up-front fee paid	$ 370,000,000.0
Milestone fee payments upon achievement of various development and commercialization	1,380,000,000
Transaction price of license		370,000,000.0		370,000,000.0
Change in transaction price		0
Abb Vie Collaboration And License Agreement | Other Current Assets [Member]
License Revenue [Line Items]
Net cost reimbursement due from collaborators		18,200,000		6,200,000
Due from Abeona		18,200,000		6,200,000
Novartis License Agreement [Member] | Novartis Gene Therapies [Member]
License Revenue [Line Items]
Accounts receivable		18,000,000.0		27,300,000
November Two Thousand Eighteen License Agreement | Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Settlement agreement payable		30,000,000.0
November Two Thousand Twenty One License Agreement | Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Settlement agreement payable		20,000,000.0
November Two Thousand Twenty Two License Agreement | Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Settlement agreement payable		5,000,000.0
November Two Thousand Twenty Four License Agreement | Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Settlement agreement payable		5,000,000.0
Settlement Agreement | Abeona Therapeutics Incorporation
License Revenue [Line Items]
Accounts receivable		4,300,000
Accounts receivable, Non-current		4,300,000		4,200,000
Payments due from related party		5,000,000.0
Allowance for credit losses		4,300,000		4,200,000
Provision for credit losses		0	$ 0
Sales Based Milestones | Abb Vie Collaboration And License Agreement
License Revenue [Line Items]
Milestone fee payments upon achievement of various development and commercialization	820,000,000.0
Transaction price of license		820,000,000.0		820,000,000.0
Development Milestone | Abb Vie Collaboration And License Agreement
License Revenue [Line Items]
Milestone fee payments upon achievement of various development and commercialization	$ 562,500,000
Transaction price of license		562,500,000		$ 562,500,000
Maximum [Member]
License Revenue [Line Items]
Aggregate milestone payment for all the targets		$ 1,560,000
N A V Technology Platform [Member]
License Revenue [Line Items]
Number of commercial product candidates | ProductCandidate		1
HCR [Member] | Novartis License Agreement [Member] | Novartis Gene Therapies [Member]
License Revenue [Line Items]
Accounts receivable, current		$ 13.0